COMPARISON BETWEEN SHORT-TERM RENAL HEMODYNAMIC-EFFECTS OF PROPRANOLOL AND NADOLOL IN ESSENTIAL-HYPERTENSION - A CROSSOVER STUDY

被引:17
作者
DANESH, BJZ
BRUNTON, J
SUMNER, DJ
机构
[1] STOBHILL GEN HOSP, DIV MED, GLASGOW G21 3UW, SCOTLAND
[2] W SCOTLAND HLTH BOARDS, DEPT CLIN PHYS & BIOENGN, GLASGOW G4 9LF, SCOTLAND
关键词
D O I
10.1042/cs0670243
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The effect of 4-6 wk treatment with propranolol and nadolol on effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) was studied, in 14 patients with essential hypertension, in single blind, random and cross-over design. Both drugs caused comparable effective lowering of pulse and blood pressure. When taken as the 1st drug, propranolol caused significant reduction in ERPF and GFR and a rise in filtration fraction (FF) and renal vascular resistance (RVR), whereas nadolol caused distinct rise in ERPF and a fall in FF and RVR, but GFR remained unchanged. These hemodyamic effects were reduced when propranolol was given immediately after the withdrawal of nadolol and were obviated when nadolol followed propranolol therapy. This suggested a carry-over effect of the 1st drug into the 2nd phase of treatment. With short term therapy in essential hypertension, propranolol apparently has a renal vasoconstrictor and nadolol a vasodilator effect.
引用
收藏
页码:243 / 248
页数:6
相关论文
共 33 条
  • [1] ABDELRAZZAK M, 1977, ARCH INT PHARMACOD T, V229, P227
  • [2] LONG-TERM EFFECT OF PROPRANOLOL THERAPY ON RENAL-FUNCTION
    BAUER, JH
    BROOKS, CS
    [J]. AMERICAN JOURNAL OF MEDICINE, 1979, 66 (03) : 405 - 410
  • [3] BRITTON KE, 1981, LANCET, V2, P900
  • [4] THE CLINICAL IMPORTANCE OF CARDIOSELECTIVITY AND LIPOPHILICITY IN BETA-BLOCKERS
    CRUICKSHANK, JM
    [J]. AMERICAN HEART JOURNAL, 1980, 100 (02) : 160 - 178
  • [5] DUCHIN K, 1978, CIRCULATION, V58, P183
  • [6] PROSTAGLANDINS AND KIDNEY
    DUNN, MJ
    HOOD, VL
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1977, 233 (03): : F169 - F184
  • [7] FENYVESI T, 1970, ACTA PHYSIOL HUNG, V38, P159
  • [8] HARRIES JD, 1972, P SOC EXP BIOL MED, V140, P1148
  • [9] HEIERLI C, 1977, INT J CLIN PHARM BI, V15, P65
  • [10] 2-PERIOD CROSSOVER CLINICAL-TRIAL
    HILLS, M
    ARMITAGE, P
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 8 (01) : 7 - 20